Business Wire

Aker BP Leverages Cognite Atlas AI™ to Pioneer an AI-First Future in Exploration and Production

16.9.2025 15:00:00 CEST | Business Wire | Press Release

Share

Aker BP, one of Europe's largest independent oil companies, and Cognite, the global leader in industrial AI, deepen their strategic partnership through the expanded adoption of Cognite Atlas AI™,harnessing the power of AI agents to improve efficiency, reduce costs, and elevate productivity. This enhanced collaboration puts Aker BP at the forefront of leveraging agentic AI to drive significant value and transform its operations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903134233/en/

Aker BP Leverages Cognite Atlas AI™ to Pioneer an AI-First Future in Exploration and Production

Aker BP's "AI-first strategy" was developed to help lead the energy sector into a data-driven future by seamlessly integrating AI applications within industrial settings and business objectives to innovate and deliver results across the business. This includes automating complex processes and allowing engineers to easily access industrial expertise.

"Our collaboration with Cognite on Atlas AI represents a significant leap forward in our digital transformation journey," said Paula Doyle, Chief Digital Officer, Aker BP. "This partnership underscores our commitment to a continued AI-first, data-driven approach with Cognite, embracing agentic AI to further drive efficiency, enhance decision-making, and optimize our operations across the board."

Cognite Atlas AI offers pre-built agents and a low-code workbench for building industrial AI agents, accelerating the journey towards autonomous operations. Integrated with the robust data foundation provided by Cognite Data Fusion®, the collaboration supports Aker BP's span of various strategic areas where AI is being leveraged to drive significant operational advancements and value.

This AI-first partnership includes streamlining critical workflows by automating document processing for enhanced supply chain efficiency and proactive barrier management. This includes initiatives like automatic equipment registration, which has the potential to reduce a significant number of engineering hours for Aker BP. Building an AI-ready data foundation for predictive maintenance and using AI to optimize production chemistry and overall performance is also underway.

The most recent collaboration includes creating AI agents for root cause analysis (RCA). These agents identify relevant information, create cause maps, and suggest RCA steps. These agents reduce engineers' time to perform this analysis by over 70%.

"We tested other AI solutions, but they fell short," said Tor Arne Amdal, Senior Reliability Engineer at AkerBP. "What we needed was contextualized intelligence. In our industrial work, it's not enough to just have data; you need the right data, in the right context, at the right time. This combination provides the precise, reliable answers that help us make faster decisions. After testing various solutions, we chose Cognite because it could meet our specific needs for AI-supported RCA workflows."

"Aker BP's legacy isn't just about being a digital leader; it's about pioneering the future," said Francois Laborie, EVP, Strategic Projects, Cognite. "This partnership is a powerful testament to their unwavering commitment to an AI-first strategy. By merging Aker BP's deep industry expertise with Cognite's Atlas AI, we're doing more than just solving today's challenges—we're equipping them with the internal competence to scale AI across their entire business, fundamentally empowering their workforce for tomorrow."

Witness firsthand how agentic AI is transforming industrial operations and hear directly from Aker BP and other industry leaders at Cognite's Industrial AI and Data Conference Impact 2025.

About Aker BP
Aker BP is a company engaged in exploration, field development, and production of oil and gas on the Norwegian continental shelf. The company operates the field centres Valhall, Ula, Edvard Grieg/Ivar Aasen, Alvheim, and Skarv, and is a partner in the Johan Sverdrup field. Measured in production, Aker BP is one of the largest independent oil companies in Europe.

About Cognite
Cognite makes GenAI work for industry. Leading energy, manufacturing, and power & renewables enterprises choose Cognite to deliver secure, trustworthy, and real-time data to transform their asset-heavy operations to be safer, more sustainable, and profitable. Cognite provides a user-friendly, secure, and scalable platform that makes it easy for all decision-makers, from the field to remote operations centers, to access and understand complex industrial data, collaborate in real-time, and build a better tomorrow. Visit us at www.cognite.com, and follow us on LinkedIn and X.

About Cognite Atlas AI™
Cognite Atlas AI™ unlocks the full potential of industrial data, empowering teams to make faster, more confident decisions and accelerate operational efficiency and innovation at scale. Cognite Atlas AI includes a growing library of preconfigured agents, a low-code agent builder, purpose-built industrial tools, and a curated selection of LLMs with benchmarking. It also utilizes the real-time OT, IT, and engineering data in Cognite Data Fusion®, ensuring that agents deliver accurate, traceable, and trustworthy results for industrial workflows.

To learn more about enabling agents for industry, please see the "Cognite Atlas AI" Definitive Guide to Industrial Agents and visit https://www.cognite.com/en/product/atlas.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250903134233/en/

Contacts

Media Contact:
Michelle Holford, VP of Global PR
michelle.holford@cognite.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye